×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
IOVA – iovance biotherapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
IOVA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/7
09:31 am
iova
Assessing Iovance Biotherapeutics (IOVA) Valuation After Recent Share Price Volatility [Yahoo! Finance]
Low
Report
Assessing Iovance Biotherapeutics (IOVA) Valuation After Recent Share Price Volatility [Yahoo! Finance]
2/6
11:12 am
iova
Iovance Biotherapeutics (IOVA) Gives Update on Revenue Guidance, Lung Cancer Cure [Yahoo! Finance]
Low
Report
Iovance Biotherapeutics (IOVA) Gives Update on Revenue Guidance, Lung Cancer Cure [Yahoo! Finance]
2/5
05:15 pm
iova
Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma
Medium
Report
Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma
2/5
08:04 am
iova
Iovance Biotherapeutics (NASDAQ:IOVA) had its "sell" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
Medium
Report
Iovance Biotherapeutics (NASDAQ:IOVA) had its "sell" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
1/16
05:15 pm
iova
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Medium
Report
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
1/16
05:31 am
iova
Iovance Biotherapeutics (IOVA) Is Down 14.9% After Governance Scrutiny And Equity Raise Plan Is Revealed [Yahoo! Finance]
Medium
Report
Iovance Biotherapeutics (IOVA) Is Down 14.9% After Governance Scrutiny And Equity Raise Plan Is Revealed [Yahoo! Finance]
1/15
11:53 pm
iova
Iovance Biotherapeutics (IOVA) Valuation Check After Amtagvi Outlook Reaffirmation And Governance Concerns [Yahoo! Finance]
Medium
Report
Iovance Biotherapeutics (IOVA) Valuation Check After Amtagvi Outlook Reaffirmation And Governance Concerns [Yahoo! Finance]
1/15
02:36 pm
iova
Iovance Biotherapeutics, Inc. (IOVA): A Bull Case Theory [Yahoo! Finance]
Low
Report
Iovance Biotherapeutics, Inc. (IOVA): A Bull Case Theory [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
11/6/2025
08:00 am
iova
iovance biotherapeutics, inc.
BEAT
Report
16.7%
iovance biotherapeutics, inc.
8/7/2025
04:01 pm
iova
iovance biotherapeutics, inc.
MISS
Report
-20.7%
iovance biotherapeutics, inc.
2/27/2025
04:01 pm
iova
iovance biotherapeutics, inc.
BEAT
Report
-19.5%
iovance biotherapeutics, inc.
2/27/2025
04:01 pm
iova
iovance biotherapeutics, inc.
BEAT
Report
-19.5%
iovance biotherapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/9
06:43 am
iova
Form SCHEDULE 13G IOVANCE BIOTHERAPEUTICS, Filed by: STATE STREET CORP
Low
Report
Form SCHEDULE 13G IOVANCE BIOTHERAPEUTICS, Filed by: STATE STREET CORP
1/9
07:36 am
iova
Form 8-K IOVANCE BIOTHERAPEUTICS, For: Jan 09
Medium
Report
Form 8-K IOVANCE BIOTHERAPEUTICS, For: Jan 09
12/3
05:04 pm
iova
Form 4 IOVANCE BIOTHERAPEUTICS, For: Dec 01 Filed by: GRAF FINCKENSTEIN FRIEDRICH
Neutral
Report
Form 4 IOVANCE BIOTHERAPEUTICS, For: Dec 01 Filed by: GRAF FINCKENSTEIN FRIEDRICH
12/3
05:03 pm
iova
Form 4 IOVANCE BIOTHERAPEUTICS, For: Dec 01 Filed by: BILINSKY IGOR
Neutral
Report
Form 4 IOVANCE BIOTHERAPEUTICS, For: Dec 01 Filed by: BILINSKY IGOR
12/3
05:01 pm
iova
Form 4 IOVANCE BIOTHERAPEUTICS, For: Dec 01 Filed by: Vogt Frederick G
Neutral
Report
Form 4 IOVANCE BIOTHERAPEUTICS, For: Dec 01 Filed by: Vogt Frederick G
12/3
05:01 pm
iova
Form 4 IOVANCE BIOTHERAPEUTICS, For: Dec 01 Filed by: Puri Raj K.
Neutral
Report
Form 4 IOVANCE BIOTHERAPEUTICS, For: Dec 01 Filed by: Puri Raj K.
11/12
05:02 pm
iova
Form S-8 IOVANCE BIOTHERAPEUTICS,
Medium
Report
Form S-8 IOVANCE BIOTHERAPEUTICS,
11/12
05:01 pm
iova
Form S-8 IOVANCE BIOTHERAPEUTICS,
Medium
Report
Form S-8 IOVANCE BIOTHERAPEUTICS,
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
5/15
Iovance Biotherapeutics Announces Updates to Tumor Infiltrating Lymphocyte (TIL) Therapy Clinical Programs
36.1%
2/24 Form SC 13G/A IOVANCE BIOTHERAPEUTICS, Filed by: Avoro Capital Advisors LLC 27.4%
4/13 Iovance Biotherapeutics Announces H. Lee Moffitt Cancer Center to Present Lung Cancer Clinical Data at American Association for Cancer Research (AACR) Virtual Annual Meeting 2020 17.5%
11/7 Iovance Biotherapeutics to Present at Upcoming Investor Conferences in November 15.8%
3/23 Novan up 27% on favorable safety profile of SB206, Covid-19 plan [Seeking Alpha] 11.6%
2/25 Iovance Biotherapeutics, Inc. (IOVA) CEO Maria Fardis on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] 10.3%
1/8 Iovance Biotherapeutics Inc (NASDAQ: IOVA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 8.4%
6/3 Iovance Biotherapeutics Inc (NASDAQ: IOVA) had its price target raised by analysts at HC Wainwright from $26.00 to $32.00. They now have a "buy" rating on the stock. 8.0%
10/2 Iovance Biotherapeutics Announces Four Abstracts to be Presented at the Upcoming 2019 SITC Annual Meeting 6.9%
11/4 Q3/2019 9/30/2019 EPS -0.400 ZacksConsensus -0.400 ActVsEst 0.000 - In-Line 6.6%
2/24 Form SC 13G/A IOVANCE BIOTHERAPEUTICS, Filed by: Avoro Capital Advisors LLC 27.4%
4/13 Iovance Biotherapeutics Announces H. Lee Moffitt Cancer Center to Present Lung Cancer Clinical Data at American Association for Cancer Research (AACR) Virtual Annual Meeting 2020 17.5%
11/7 Iovance Biotherapeutics to Present at Upcoming Investor Conferences in November 15.8%
3/23 Novan up 27% on favorable safety profile of SB206, Covid-19 plan [Seeking Alpha] 11.6%
2/25 Iovance Biotherapeutics, Inc. (IOVA) CEO Maria Fardis on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] 10.3%
1/8 Iovance Biotherapeutics Inc (NASDAQ: IOVA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 8.4%
6/3 Iovance Biotherapeutics Inc (NASDAQ: IOVA) had its price target raised by analysts at HC Wainwright from $26.00 to $32.00. They now have a "buy" rating on the stock. 8.0%
10/2 Iovance Biotherapeutics Announces Four Abstracts to be Presented at the Upcoming 2019 SITC Annual Meeting 6.9%
11/4 Q3/2019 9/30/2019 EPS -0.400 ZacksConsensus -0.400 ActVsEst 0.000 - In-Line 6.6%
TOP News Decliners
3/16
Iovance Biotherapeutics Inc (NASDAQ: IOVA) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating.
-20.2%
1/12 BRIEF-Iovance Biotherapeutics Obtains License To Develop And Commercialize A Novel IL-2 Analog [Reuters] -14.5%
5/31 Iovance Biotherapeutics Inc (NASDAQ: IOVA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $30.00 price target on the stock. -10.9%
4/28 Frazier Healthcare Partners Adds Experienced Capital Markets Executive to Life Sciences Team -10.0%
9/25 Form EFFECT IOVANCE BIOTHERAPEUTICS, -8.1%
8/1 Form 8-K IOVANCE BIOTHERAPEUTICS, For: Aug 01 -6.9%
6/11 Iovance Biotherapeutics Appoints Athena Countouriotis, M.D., to Board of Directors -5.3%
8/2 Iovance Biotherapeutics, Inc. (IOVA) Q2 2019 Earnings Call Transcript [The Motley Fool] -5.1%
4/27 Iovance Biotherapeutics Inc (NASDAQ: IOVA) had its price target raised by analysts at Chardan Capital from $36.00 to $44.00. They now have a "buy" rating on the stock. -4.5%
11/21 Iovance Biotherapeutics Announces Results of a Subgroup Analysis of Patients in the Lifileucel Metastatic Melanoma Study who are Primary Refractory to Anti-PD-1/L1 Therapy -4.4%
1/12 BRIEF-Iovance Biotherapeutics Obtains License To Develop And Commercialize A Novel IL-2 Analog [Reuters] -14.5%
5/31 Iovance Biotherapeutics Inc (NASDAQ: IOVA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $30.00 price target on the stock. -10.9%
4/28 Frazier Healthcare Partners Adds Experienced Capital Markets Executive to Life Sciences Team -10.0%
9/25 Form EFFECT IOVANCE BIOTHERAPEUTICS, -8.1%
8/1 Form 8-K IOVANCE BIOTHERAPEUTICS, For: Aug 01 -6.9%
6/11 Iovance Biotherapeutics Appoints Athena Countouriotis, M.D., to Board of Directors -5.3%
8/2 Iovance Biotherapeutics, Inc. (IOVA) Q2 2019 Earnings Call Transcript [The Motley Fool] -5.1%
4/27 Iovance Biotherapeutics Inc (NASDAQ: IOVA) had its price target raised by analysts at Chardan Capital from $36.00 to $44.00. They now have a "buy" rating on the stock. -4.5%
11/21 Iovance Biotherapeutics Announces Results of a Subgroup Analysis of Patients in the Lifileucel Metastatic Melanoma Study who are Primary Refractory to Anti-PD-1/L1 Therapy -4.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: